Drugs / HMM910
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06949137 | Jun 2025 → Mar 2026 overdue | postmenopausal osteoporosis | HELP Therapeutics Co., Ltd. | Active not recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | HMM910 | “human umbilical cord-derived mesenchymal stem cells for injection (HMM910 )” NCT06949137 ↗ |
| Modality | Cell therapy | “human mesenchymal stem cells” NCT06949137 ↗ |
| Route | Intravenous | “Intravenous infusion of human mesenchymal stem cells (HMM910 ) at 20-25 drops per minute” NCT06949137 ↗ |